← Back to Search

Diuretic

Acetazolamide for Obstructive Sleep Apnea (RemmOSA Trial)

Phase 1 & 2

Recruiting

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 night

Awards & highlights

RemmOSA Trial Summary

This trial will test a new treatment to reduce severity of OSA, a highly prevalent disorder with serious consequences. It will look at the effect of Acetazolamide on REM and nREM OSA and on ventilatory parameters.

Who is the study for?

This trial is for people with REM sleep apnea who haven't used CPAP for over a week. Participants should have more severe symptoms during REM than non-REM sleep and not be on any medication that affects breathing or have conditions like uncontrolled medical issues, major neurological disorders, heart failure, respiratory diseases other than sleep apnea, or be pregnant.Check my eligibility

What is being tested?

The study tests if Acetazolamide can help with REM-related obstructive sleep apnea by improving muscle activity in the airway and breathing drive during sleep. It's compared to a placebo capsule to see if there's a real effect.See study design

What are the potential side effects?

Acetazolamide may cause side effects such as acidosis (too much acid in the body), low potassium levels, low sodium levels, adrenal gland problems, kidney function impairment, allergic reactions if sensitive to sulfa drugs, liver disease complications.

RemmOSA Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 night

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 night

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 night for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Apnea hypopnea index

Genioglossus activity in REM and NREM

Hypoxia

+1 more

RemmOSA Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: AcetazolamideActive Control1 Intervention

Acetazolamide 250 mg before bedtime 3 nights before the study, Acetazolamide 500 mg before bedtime for 2 nights before the study (inclusive)

Group II: PlaceboPlacebo Group1 Intervention

Placebo capsule before bedtime for 3 nights before the studies (inclusive)

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor

1,616 Previous Clinical Trials

11,470,940 Total Patients Enrolled

Media Library

Acetazolamide (Diuretic) Clinical Trial Eligibility Overview. Trial Name: NCT05589792 — Phase 1 & 2

Obstructive Sleep Apnea Research Study Groups: Placebo, Acetazolamide

Obstructive Sleep Apnea Clinical Trial 2023: Acetazolamide Highlights & Side Effects. Trial Name: NCT05589792 — Phase 1 & 2

Acetazolamide (Diuretic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05589792 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I potentially take part in this investigation?

"This medical research seeks 10 individuals with obstructive sleep apnea (OSA) aged between 21 and 75. Criteria for eligibility include a REM AHI/nREM AHI score of at least 2, an average duration of REM sleep longer than 10 minutes, and no usage of CPAP for more than 1 week."

Answered by AI

Are there still opportunities to join this clinical examination?

"As per the information found on clinicaltrials.gov, this medical trial is not currently seeking participants. This particular study was first announced in December 1st 2022 and last edited October 20th 2022; nonetheless, 284 other trials are still actively recruiting patients at present."

Answered by AI

Is admittance to this medical experiment open to geriatric participants?

"The requirements for enrollment in this medical trial stipulate that patients must be between 21 and 75 years of age. The study features 42 studies for minors, as well as 234 studies specifically targeting those above 65 years old."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Acetazolamide on REM OSA

Ludovico Messineo, MD 2023. "Acetazolamide on REM OSA". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05589792.